Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 1998

View Archived Issues

The role of Ca2+-activated K+ channels in bronchorelaxation by NKH-477

Nabi: Q4 and year-end 1997 highlights

Cantab: year-end 1997 highlights

MRX-115 allows for accurate assessment of AMI in dogs

NeuroSearch: year-end 1997 highlights

Inhibitors of selectin binding and cell adhesion prepared at Nippon Shinyaku

Zadaxin shows wound-healing properties

Nikken Chemicals develops new agents for asthma

Improved agents for schizophrenia developed at Yoshitomi

SangStat and Dyax enter license agreement

p24-VLP safe but not immunogenic in phase II trials

Depsipeptides useful in dementia under evaluation at Nisshin Flour Milling

Cardiovascular disease gene discovered

Third phase II trial begins of ONYX-015 in head and neck cancer

Company Profile: Angiotech

Fortovase cited as preferred therapy in AIDS guidelines

Aricept launched in France

Aquila Biopharmaceuticals: Q4 and year-end 1997 highlights

Glaxo Wellcome researches MMP inhibitors

Neuroprotective glutamate antagonists from Warner-Lambert

Novartis describes new thrombin inhibitors

Enbrel safety established in juvenile RA patients; efficacy data now being generated

Zenapax launched in Switzerland

Lidakol NDA accepted for review

Phase II trial begins with rPAF-AH in pancreatitis

Abbott announces intention to acquire Murex

AIDS patients will have expanded access to Ziagen

Isis reports incident of data manipulation; clinical progress will not be affected

Nuvance stabilizes lung function in asthmatic patients

Spherons: a time bomb in the human brain?

Merck & Co. obtains improved analogues of montelukast

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...